SHINE Technologies’ large-scale medical isotope manufacturing facility under construction in Janesville could be online by the middle of next year.

The U.S. Nuclear Regulatory Commission has issued its final safety evaluation report related to the operating license application for SHINE’s building on the south side.

When The Chrysalis is fully operational, the company plans to produce medical isotopes, including molybdenum-99, which powers more than 40 million medical procedures annually to diagnose heart disease, cancer, and other diseases.

Founder and CEO Greg Piefer says this milestone has been 10 years in the making.